August 16, 2017 6:21pm
While stepping on no cracks and having thrown salt over its shoulder
Walk carefully; there is still one heck of a lot of risk in “our” sector
Pre-open indications: 3 hit and 2 miss
Out and about; Cytori Therapeutics (CYTX) files a rights offering. Another CEO and management team LOSER trying to keep their oversized pay checks! Biostage’s (BSTG) share price keeps dropping also with an S-1 priced at $0.315
It’s called premium content for a reason … I define insight from a real-time perspective discussing equity share pricing, attractiveness and support levels as stock pricing changes by the hour … if not the minute!
Others don’t even come close!
I answer one question, in which company should investors commit and keep their money.
Wednesday’s results have implications to Thursday’s sector activity as a daily report may say little or a lot and it serves as insurance that all indications are being examined and evaluated!
Henry’omics:
From the pre-open’s investor’s newsletter, “… shuffling ahead with no clear direction. Mr. 15% … says if you don’t see clearly or feel it… don’t chase a sector trade.”
- A few companies with their abject failures and their audacity to seek further funding are casting aspersions upon the sector as a whole!
The issue is … the sector is gauging the remainder of August through September – a dangerous time!
- The issue is uncertain (when isn’t it) and BELIEVEABILITY of many a CEO as to their actions and initiatives that haven’t been … “GUIDED” to its shareholders.
Same old story and that is why – believability has CEMENTED negative sentiment!
Out and about:
Cytori Therapeutics readies rights offering; shares down 5.14%
- Cytori Therapeutics (CYTX -$0.02 or 5.14%) filed an S-1 with the SEC in preparation for an offering of subscription rights to purchase units to current shareholders. Each unit will consist of one share of Series B Preferred Stock and one (or part of one) warrant purchasing one common share.
- Price and terms have yet to be released.
- Another CEO and management team LOSER trying to keep their oversized pay checks!
Biostage’s (BSTG) share price keeps dropping -$0.0011 to $0.35 also with an S-1 priced at $0.315
- Who would sign–up for this offering without an adjudication of their terminal death suit as its filed dismissal – hasn’t been acted on
The advance/decline line scenario of 43 SCGT & RT covered companies:
· The first hour was positive with an A/DL of 19/18 and 6 flats;
· The mid-day was positive with an A/DL of 25/12 and 6 flat;
· The close was neutral with an A/DL of 21/21 and 1 flat;
Pre-open indications: 3 hit and 2 miss
- Biostage (BSTG) closed down another -$0.0011 – hit;
- BioLife Solutions (BLFS) closed up +$0.21 – hit;
- bluebird bio (BLUE) closed up +$0.05 – miss;
- Mesoblast (MESO) closed up +$0.19 – hit;
- Kite Pharma (KITE) closed up +1.29 – miss;
Regenerative Medicine Earnings Scorecard - Q2/2017 - to date … 30 out of 43 covered – so far
http://www.regmedinvestors.com/articles/9841
Daily analytics:
U.S. stocks closed moderately higher Wednesday, restoring the Dow above the psychologically-important 22,000 mark, after Fed minutes suggested that the central bank is wrestling with sluggish inflation but eager to commence an unwind of its $4.5 trillion asset portfolio.
- The market’s gains came after a volatile session, reflecting uncertainty about the strategic path for the central bank and political tensions facing President Trump that could disrupt his pro-growth agenda.
The S&P 500 SPX, +0.14% rose 3.5 points, or 0.1%, to close at 2,468.11. The Dow climbed 25.88 points, or 0.1%, to end at 22,024.87, extending its winning streak to a fourth session. The NASDAQ rose 12.10 points, or 0.2%, to close at 6,345.11.
The CBOE Volatility Index (VIX) widely considered the best gauge of fear in the market, traded at 11.74, down -2.49% …
- Tuesday traded at 12.04, down -2.35% … after Monday traded at 12.38 and was down -20.18% …Friday traded at 15.51, down -3.20% following Thursday’s 16.04, a +44.37% increase and last Wednesday traded at 11.19, up +2.10%
Welcome to another day of the sector’s roller coaster …
… The iShares Russell 2000 (IWM) indicated:
· Wednesday +0.04%
· Tuesday -0.81%
· Monday +1.49%
· Friday +0.15%
· Thursday -1.82%
· Last Wednesday -0.86%
… The iShares NASDAQ Biotechnology (IBB) indicated:
· Wednesday was up +0.25%
· Tuesday +0.09%
· Monday +1.03%
· Friday +0.64%
· Thursday -2.82%
· Last Wednesday -0.32%
The count - decliners versus gainers:
……. look at the differences in the spreads as decliners jump and %’s migrate…
· Wednesday’s decliners ranged from -0.31% <BSTG> to -5.36% <SGMO> in 21 equities;
· Tuesday’s decliners ranged from -0.38% <FCSC> to -15.29% <BSTG> in 24 equities;
· Monday’s decliners ranged from -0.24% <RGNX> to -17.71% <BSTG> in 12 equities;
· Friday’s decliners ranged from -0.46% <KITE> to -11.97% <IMUC> in 14 equities;
· Thursday’s decliners ranged from -0.31% <KITE> to -11.52% <VSTM> in 33 equities;
· Last Wednesday’s decliners ranged from -0.16% <OSIR> to -21.24% <BLCM> in 31 equities;
Versus
… Look at the percentage’s (%) and spreads …
· Wednesday’s gainers ranged from +0.05% <BLUE> to +7.44% <IMUC> in 21 equities;
· Tuesday’s gainers ranged from +0.43% <XON> to +6.08% <MDXG> in 15 equities;
· Monday’s gainers ranged from +0.88% <ADRO> to +26% <IMUC> in 28 equities;
· Friday’s gainers ranged from +0.06% <BSTG> to +11.43% <CUR> in 28 equities;
· Thursday’s gainers ranged from +0.32% <OSIR> to +12.43% <SGMO> in 8 equities;
· Last Wednesday’s gainers ranged from +0.71% <KITE> to +13.33% <VCEL> in 10 equities;
Some of MY working trend lines or indications:
… The greatest volume to the downside: SGMO, JUNO, XON, ONVO and ATHX
… Upside volume was weighted to: MDXG, IMUC, PSTI, KITE and BLCM
… Biggest $ downside: JUNO, SGMO, XON, STML and QURE
… Largest $ upside: KITE, ONCE, RGNX, BLCM and BLFS
… Flat: RENE.L
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.